Survival time and related factors among child HIV/AIDS patients in Anhui province
-
摘要:
目的 了解安徽省儿童艾滋病患者的生存状况及影响因素。 方法 采用回顾性队列研究方法,收集“中国艾滋病综合防治信息系统”中报告的截止到2020年12月31日现住址为安徽省的儿童艾滋病患者数据资料,采用寿命表法计算生存率,Cox 比例风险模型分析其影响因素。 结果 共纳入329例儿童艾滋病患者,54 例死亡,艾滋病相关病死率为2.2/100人年。Cox 比例风险模型分析显示,儿童艾滋病患者生存时间与诊断时疾病状态、是否接受抗病毒治疗有关,诊断时疾病状态为艾滋病的死亡风险是感染者的5.32倍,未接受抗病毒治疗是接受治疗的28.29倍。接受抗病毒治疗儿童艾滋病患者生存时间与诊断时年龄、诊断时疾病状态、治疗前基线CD4 + T淋巴细胞计数有关,诊断时年龄 < 5岁的死亡风险是11~15岁的6.18倍,诊断时疾病状态为艾滋病是感染者的5.07倍,治疗前基线CD4 + T淋巴细胞计数介于50~200、 < 50个/μL分别是 > 200个/μL的8.40倍和10.99倍。 结论 抗病毒治疗是影响儿童艾滋病患者生存时间的重要因素,治疗前基线CD4 + T淋巴细胞计数水平是影响治疗效果的关键因素。 Abstract:Objective To examine the survival time of child human immunodeficiency virus (HIV)/AIDS patients and its influencing factors in Anhui province. Methods Follow-up and medication information on all laboratory confirmed AIDS patients aged ≤ 15 years at the diagnosis and being permanent residents of Anhui province were collected from National Comprehensive HIV/AIDS Information Management System up to the end of 2020 and analyzed retrospectively. The survival rate was calculated with life table method and impact factors of survival were assessed using Cox regression model. Results Among a total of 329 child HIV/AIDS patients being followed-up during the period, 54 died of AIDS-related diseases and the mortality rate was 2.2/100 person-years. The results of Cox proportional hazards regression analysis showed that for all the child patients, the children with AIDS at the time of first diagnosis and not receiving antiretroviral therapy were at a significantly higher risk of AIDS-related disease mortality, with the hazard ratio (HR) of 5.32 (95% confidence interval [95% CI] : 2.70 – 10.47) and 28.29 (95% CI : 14.63 – 54.70) compared to those not having AIDS at the first diagnosis and to those receiving antiretroviral therapy; among the child patients with antiretroviral therapy, the risk of AIDS-related disease mortality were significantly higher for those aged < 5 years at the first diagnosis (versus aged 11 – 15 years: HR = 6.18, 95% CI : 14.63 – 54.70 ), having AIDS at the first diagnosis (versus having HIV infection: HR = 5.07, 95% CI : 1.27 – 20.29), and with the baseline CD4 + T lymphocyte count of < 50 cells/μL (HR = 10.99, 95% CI : 2.04 – 59.20) or 50 – 200 cells/μL (HR = 8.40, 95% CI : 1.35 – 52.26) compared to the child patients with the baseline count of > 200 cells/μL, respectively. Conclusion Among child HIV/AIDS patients in Anhui province, antiretroviral therapy is an important factor for survival and the baseline CD4 + T lymphocyte count is the key factor affecting the effect of antiretroviral therapy. -
表 1 影响儿童艾滋病患者生存时间的Cox回归分析
变量 例数 % 单因素分析 多因素分析 β P 值 HR 95 % CI β P 值 HR 95 % CI 诊断时年龄(岁) <5 140 42.6 – 0.28 0.475 0.76 0.35~1.63 0.01 0.978 1.01 0.47~2.19 5~10 127 38.6 0.11 0.774 1.11 0.54~2.32 0.47 0.217 1.60 0.76~3.36 11~15 62 18.8 1.00 性别 男童 183 55.6 0.08 0.774 1.08 0.63~1.86 女童 146 44.4 1.00 民族 汉族 320 97.3 0.47 0.640 1.60 0.22~11.61 其他 9 2.7 1.00 感染途径 母婴传播 266 80.9 – 0.94 0.012 0.39 0.19~0.81 0.25 0.535 1.28 0.59~2.79 血液传播 28 8.5 0.29 0.533 1.33 0.54~3.29 0.36 0.448 1.44 0.56~3.67 其他/不详 35 10.6 1.00 1.00 诊断时疾病状态 感染者 184 55.9 1.00 艾滋病 145 44.1 1.73 < 0.001 5.65 2.91~10.96 1.67 < 0.001 5.32 2.70~10.47 接受抗病毒治疗 是 275 83.6 1.00 1.00 否 54 16.4 3.27 < 0.001 26.17 14.20~48.22 3.34 < 0.001 28.29 14.63~54.70 表 2 影响抗病毒治疗儿童艾滋病患者生存时间的Cox回归分析
变量 例数 % 单因素分析 多因素分析 β P 值 HR 95 % CI β P 值 HR 95 % CI 诊断时年龄(岁) < 5 116 42.2 – 0.25 0.727 0.78 0.20~3.13 1.82 0.041 6.18 1.01~38.58 5~10 107 38.9 0.22 0.737 1.25 0.34~4.62 1.66 0.063 5.26 0.92~0.243 11~15 52 18.9 1.00 1.00 性别 男童 145 52.7 – 0.60 0.218 0.55 0.21~1.42 女童 130 47.3 1.00 1.00 民族 汉族 267 97.1 3.06 0.592 21.30 0.00~156.84 其他 8 2.9 1.00 感染途径 母婴传播 235 85.5 0.23 0.825 1.26 0.17~9.52 – 0.42 0.716 0.66 0.07~6.24 血液传播 15 5.5 0.07 0.963 1.07 0.07~17.23 – 14.34 0.987 0.00 0.00~0.00 其他/不详 25 9.0 1.00 1.00 诊断时疾病状态 感染者 166 60.4 1.00 1.00 艾滋病 109 39.6 1.65 0.004 5.19 1.71~15.77 1.62 0.022 5.07 1.27~20.29 治疗前基线
CD4 + T计数(个/μL)< 50 39 16.9 2.12 0.011 8.34 1.62~43.03 2.13 0.023 10.99 2.04~59.20 50~200 54 23.4 2.22 0.005 9.19 1.95~43.38 2.40 0.005 8.40 1.35~52.26 > 200 138 59.7 1.00 1.00 使用复方新诺明 是 89 32.4 0.55 0.247 1.73 0.68~4.40 否 186 67.6 1.00 治疗前WHO临床分期 I期 107 38.9 – 1.38 0.040 0.25 0.07~0.94 II期 44 16.0 – 2.18 0.052 0.11 0.01~1.02 III期 104 37.8 – 0.99 0.107 0.37 0.11~1.24 IV期 20 7.3 1.00 初始治疗方案 一线方案 234 85.1 0.01 0.993 1.01 0.23~4.44 – 0.487 0.599 0.61 0.10~3.78 二线方案及其他 41 14.9 1.00 1.00 -
[1] 苏普玉, 陶芳标, 郝加虎, 等. 安徽农村地区曾因有偿献血感染HIV/AIDS的已婚成人心理卫生问题研究[J]. 卫生研究, 2010, 39(6): 739 – 742,746. [2] Kaufman J, Jing J. China and AIDS – the time to act is now[J]. Science, 2002, 296(5577): 2339 – 2340. doi: 10.1126/science.1074479 [3] 周信娟, 沈智勇, 阮玉华, 等. 经母婴传播艾滋病患者生存分析[J]. 中国公共卫生, 2018, 34(7): 964 – 967. [4] 杨壁珲, 张米, 舒远路, 等. 云南省接受抗病毒治疗的艾滋病患儿10年死亡风险及其预测因素分析[J]. 中华传染病杂志, 2019, 37(1): 28 – 31. [5] Njom Nlend AE, Loussikila AB. Predictors of mortality among HIV - infected children receiving highly active antiretroviral therapy[J]. Médecine et Maladies Infectieuses, 2017, 47(1): 32 – 37. [6] 尹浩, 马烨, 杨萱, 等. 我国14岁及以下HIV感染儿童生存分析[J]. 中华流行病学杂志, 2020, 41(6): 850 – 855. doi: 10.3760/cma.j.cn112338-20191129-00844 [7] 陈亮, 张明雅, 严延生. 福建省2003 — 2015年儿童HIV/AIDS病例生存时间分析[J]. 中国公共卫生, 2016, 32(12): 1605 – 1608. doi: 10.11847/zgggws2016-32-12-01 [8] Chaimay B, Woradet S, Chantutanon S, et al. Clinical risk factors on survival among HIV - infected children born to HIV - infected mothers[J]. Journal of the Medical Association of Thailand, 2013, 96(11): 1434 – 1443. [9] Arage G, Assefa M, Worku T, et al. Survival rate of HIV - infected children after initiation of the antiretroviral therapy and its predictors in Ethiopia: a facility - based retrospective cohort[J]. SAGE Open Medicine, 2019: 7. doi: 10.1177/2050312119838957 [10] 杨薇, 栾荣生, 赖文红, 等. 2007 — 2013年四川省355例艾滋病儿童患者抗病毒治疗情况分析[J]. 预防医学情报杂志, 2018, 34(2): 227 – 231. [11] 孙定勇, 杨文杰, 马彦民, 等. 2003 — 2014年河南省14岁及以下艾滋病抗病毒治疗患者生存分析[J]. 中华预防医学杂志, 2015, 49(8): 700 – 704. doi: 10.3760/cma.j.issn.0253-9624.2015.08.007 [12] Somi G, Majigo M, Manyahi J, et al. Pediatric HIV care and treatment services in Tanzania: implications for survival[J]. BMC Health Services Research, 2017, 17(1): 540. doi: 10.1186/s12913-017-2492-9 [13] Melaku Z, Lulseged S, Wang CH, et al. Outcomes among HIV - infected children initiating HIV care and antiretroviral treatment in Ethiopia[J]. Tropical Medicine and International Health, 2017, 22(4): 474 – 484. doi: 10.1111/tmi.12834 [14] Sandgaard KS, Lewis J, Adams S, et al. Antiretroviral therapy increases thymic output in children with HIV[J]. AIDS, 2014, 28(2): 209 – 214. doi: 10.1097/QAD.0000000000000063